Norfolk, VA, November 21, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Read MoreNorfolk, VA, November 5, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Read MoreCompany is advancing three Phase 2 clinical programs evaluating RLS-0071 in rare and acute inflammatory diseases with limited treatment options...
Read MoreIndustry veteran brings two decades of experience in business development, venture capital, and equity research with a successful track record...
Read MoreDavid Marek, a current ReAlta Board member and accomplished executive who, as CEO of Myovant Sciences, led the organization through...
Read MoreSecond clinical indication for RLS-0071 to receive both Orphan Drug Designation and Fast Track Designation, demonstrating the broad potential of...
Read MoreNew appointment brings global financial and operational experience in life sciences to support continued advancement of ReAlta’s EPICC Technology Platform...
Read MoreNorfolk, VA – March 28, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company...
Read MoreNorfolk, VA – February 21, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company...
Read More